Novogen Company Profile (NASDAQ:NVGN)

About Novogen

Novogen logoNovogen Limited (Novogen) is a drug discovery company. The Company is primarily engaged in pharmaceutical research and development. The Company's operations include CanTx Inc., its United States-based joint venture company with Yale University. Novogen has two drug technology platforms (the superbenzopyrans (SBPs) and anti-tropomyosins (ATMs)) yielding drug candidates that have application across a range of degenerative diseases. The Company's product candidates include Cantrixil, Anisina and Trilexium (TRXE-009). The Company's target indication for Cantrixil is ovarian cancer and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma. The Company primarily focuses on four therapeutic areas: oncology, degenerative diseases, regenerative medicine and autoimmune diseases. It is engaged in pre-clinical steps to undergo a Phase I study for Cantrixil, Anisina and Trilexium.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: NVGN
  • CUSIP:
Key Metrics:
  • Previous Close: $1.97
  • 50 Day Moving Average: $2.00
  • 200 Day Moving Average: $2.08
  • 52-Week Range: $1.72 - $3.09
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -98.50
  • P/E Growth: 0.00
  • Market Cap: $33.86M
  • Outstanding Shares: 17,189,000
  • Beta: -0.12
Debt:
  • Current Ratio: 27.17%
Additional Links:
Companies Related to Novogen:

Analyst Ratings

Consensus Ratings for Novogen (NASDAQ:NVGN) (?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: N/A

Analysts' Ratings History for Novogen (NASDAQ:NVGN)
Show:
DateFirmActionRatingPrice TargetDetails
9/27/2016HC WainwrightReiterated RatingBuyView Rating Details
(Data available from 9/30/2014 forward)

Earnings

Earnings History for Novogen (NASDAQ:NVGN)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Novogen (NASDAQ:NVGN)
Current Year EPS Consensus Estimate: $-0.02 EPS
Next Year EPS Consensus Estimate: $-0.02 EPS

Dividends

Dividend History for Novogen (NASDAQ:NVGN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Novogen (NASDAQ:NVGN)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Novogen (NASDAQ:NVGN)
DateHeadline
finance.yahoo.com logoConversion of Convertible Notes (NASDAQ:NVGN)
finance.yahoo.com - September 14 at 10:47 AM
News IconFDA Approves Investigational New Drug (IND) Application for Cantrixil (TRX-E-002-1) in Ovarian Cancer (NASDAQ:NVGN)
www.drugs.com - September 13 at 11:24 AM
News IconNovogen (NVGN) Boosted on Investigational Drug Application with FDA (NASDAQ:NVGN)
www.economiccalendar.com - September 12 at 6:13 PM
4-traders.com logoNovogen : FDA approves IND application for Cantrixil (NASDAQ:NVGN)
www.4-traders.com - September 12 at 11:06 AM
stockhouse.com logoNovogen Announces FDA Approves IND Application for Cantrixil in Ovarian Cancer (NASDAQ:NVGN)
www.stockhouse.com - September 12 at 11:06 AM
baystreet.ca logoNovogen (NVGN) Hikes on FDA Nod (NASDAQ:NVGN)
www.baystreet.ca - September 12 at 11:06 AM
publicnow.com logoFDA approves IND application for Cantrixil (NASDAQ:NVGN)
www.publicnow.com - September 12 at 11:06 AM
publicnow.com logoResignation/appointment of Company Secretary (NASDAQ:NVGN)
www.publicnow.com - September 12 at 11:06 AM
finance.yahoo.com logoUS FDA Approves Investigational New Drug (IND) Application for Cantrixil(TM) (TRX-E-002-1) in Ovarian Cancer (NASDAQ:NVGN)
finance.yahoo.com - September 12 at 11:06 AM
finance.yahoo.com logoNovogen secures key US drug study approval (NASDAQ:NVGN)
au.finance.yahoo.com - September 12 at 11:05 AM
publicnow.com logoNovogen appoints Scientific Advisory Board to guide development of oncology pipeline (NASDAQ:NVGN)
www.publicnow.com - September 5 at 10:42 AM
publicnow.com logoAppendix 4E and Full Year Statutory Accounts (NASDAQ:NVGN)
www.publicnow.com - August 30 at 9:52 AM
publicnow.com logoNovogen appoints Key Management Personnel to drive transition to a development-focused organisation (NASDAQ:NVGN)
www.publicnow.com - August 29 at 11:02 AM
publicnow.com logoNovogen Submits IND Application to the US FDA for Cantrixil in Ovarian Cancer (NASDAQ:NVGN)
www.publicnow.com - August 15 at 8:46 AM
nasdaq.com logoNovogen Submits IND Application For Cantrixil In Ovarian Cancer To FDA (NASDAQ:NVGN)
www.nasdaq.com - August 12 at 9:46 AM
finance.yahoo.com logoNovogen Submits Investigational New Drug (IND) Application to the US FDA For Cantrixil(TM) in Ovarian Cancer (NASDAQ:NVGN)
finance.yahoo.com - August 11 at 9:46 AM
4-traders.com logoNovogen : Graham Kelly seeks cash for new Australia oncology biotech (NASDAQ:NVGN)
www.4-traders.com - June 29 at 6:27 PM
finance.yahoo.com logoNovogen Patent Covering Anisina(TM) Has Proceeded to Grant (NASDAQ:NVGN)
finance.yahoo.com - June 13 at 8:30 PM
publicnow.com logoNovogen Patent Covering Anisina Has Proceeded to Grant (NASDAQ:NVGN)
www.publicnow.com - June 13 at 7:09 PM
News IconNovogen Limited Ads (NASDAQ:NVGN) Short Interest Decreased By 9.69% - Wall Street Hints and News (NASDAQ:NVGN)
hintsnewsnetwork.com - May 26 at 2:31 PM
publicnow.com logoEdison Investment Research Report maintains valuation as Novogen resumes 100% ownership of Cantrixil (NASDAQ:NVGN)
www.publicnow.com - May 9 at 9:38 PM
prnewswire.com logoNovogen Provides Update On Development Of Cantrixil - PR Newswire (press release) (NASDAQ:NVGN)
www.prnewswire.com - May 3 at 2:24 PM
News IconNovogen Limited Ads (NASDAQ:NVGN) Shorted Shares Decreased By 27% - B.O.D.Y Confidential (NASDAQ:NVGN)
www.bodyconfidential.com - May 3 at 2:24 PM
finance.yahoo.com logoNovogen Provides Update On Development Of Cantrixil (NASDAQ:NVGN)
finance.yahoo.com - May 1 at 10:43 PM
seekingalpha.com logoAnavex Life Sciences: Miracle Drug With A Toxic Financing Set For A Severe Decline In Price - Seeking Alpha (NASDAQ:NVGN)
seekingalpha.com - April 27 at 2:54 PM
News IconNovogen Limited Ads (NASDAQ:NVGN) Short Interest Increased By 41.32% - The Post (NASDAQ:NVGN)
www.bibeypost.com - April 23 at 2:22 PM
publicnow.com logoCantrixil (TRXE-002-1) Abstract (AACR Annual Meeting 2016) (NASDAQ:NVGN)
www.publicnow.com - April 17 at 8:36 PM
News IconWhat's Ahead for Novogen Limited (ADR) After Today's Huge Increase? - Stock Caller (NASDAQ:NVGN)
www.stockcaller.com - April 15 at 2:49 PM
investorplace.com logo6 Pharmaceuticals Stocks to Sell Now - Investorplace.com (NASDAQ:NVGN)
investorplace.com - April 8 at 2:29 PM
kcregister.com logoMorning Buzz: Momenta Pharmaceuticals Inc. (NASDAQ:MNTA), Novogen Limited (NASDAQ:NVGN), Fleetmatics ... - KC Register (NASDAQ:NVGN)
www.kcregister.com - March 24 at 2:51 PM
News IconRecap for Traders: Continental Building Products (NYSE:CBPX), WPX Energy (NYSE:WPX), Novogen Limited (NASDAQ:NVGN), Charles & Colvard (NASDAQ:CTHR) (NASDAQ:NVGN)
www.gaininggreen.com - March 23 at 1:16 PM
News IconNovogen Limited (ADR) (NASDAQ:NVGN)'s Company Shares Increased 9.55% After Low Volatility - Stock Caller (NASDAQ:NVGN)
www.stockcaller.com - March 22 at 1:44 PM
clintongazette.com logoNovogen Limited Ads (NASDAQ:NVGN) Short Interest Decreased By 10.15% - Clinton Financial (NASDAQ:NVGN)
www.clintongazette.com - March 21 at 2:11 PM
streetinsider.com logoForm 6-K NOVOGEN LTD For: Mar 17 - StreetInsider.com (NASDAQ:NVGN)
www.streetinsider.com - March 17 at 1:42 PM
News IconNovogen Limited Ads (NASDAQ:NVGN) Shorted Shares Decreased By 10.15% - RiversideGazette.com (NASDAQ:NVGN)
www.riversidegazette.com - March 17 at 1:41 PM
benzinga.com logoNovogen Receives R&D Tax Incentive Cash Refund - Benzinga (NASDAQ:NVGN)
www.benzinga.com - March 17 at 1:41 PM
finance.yahoo.com logoNovogen Receives R&D Tax Incentive Cash Refund (NASDAQ:NVGN)
finance.yahoo.com - March 16 at 10:02 PM
twst.com logoNovogen Limited: Novogen Withdraws EGM Resolution to Increase Remuneration Cap - The Wall Street Transcript (NASDAQ:NVGN)
www.twst.com - March 11 at 1:01 PM
News IconWhat's Propelling Novogen Limited (ADR) to Increase So Much? - Business Standard Tribune (NASDAQ:NVGN)
www.standardtrib.com - March 9 at 1:02 PM
News IconAnalysts maintain 5.0 on Novogen Limited (NASDAQ:NVGN) - Hints News Network (NASDAQ:NVGN)
hintsnewsnetwork.com - March 4 at 12:41 PM
News IconAnalysts Release New Consensus Estimates for Novogen Limited (NASDAQ:NVGN) - Engelwood Daily (NASDAQ:NVGN)
www.engelwooddaily.com - March 1 at 12:39 PM
News IconNovogen Limited: Target Price of 5.0 expected - Hints News Network (NASDAQ:NVGN)
hintsnewsnetwork.com - February 26 at 12:33 PM
finance.yahoo.com logoNovogen Patent Covering Cantrixil And Trilexium Has Proceeded To Grant (NASDAQ:NVGN)
finance.yahoo.com - February 19 at 12:11 AM
finance.yahoo.com logoNovogen Announces Changes to the Board with New Chairman and Deputy Chairman Appointed (NASDAQ:NVGN)
finance.yahoo.com - February 5 at 2:19 AM
finance.yahoo.com logoNovogen appoints new CEO (NASDAQ:NVGN)
au.finance.yahoo.com - December 9 at 7:56 PM
finance.yahoo.com logoNovogen Appoints Dr James Garner as Chief Executive Officer (NASDAQ:NVGN)
finance.yahoo.com - December 9 at 4:59 PM
finance.yahoo.com logoNOVOGEN LTD Financials (NASDAQ:NVGN)
finance.yahoo.com - December 8 at 1:16 PM
finance.yahoo.com logoNovogen Engages Contract Research Organisation to Conduct Cantrixil Phase 1 Clinical Trial (NASDAQ:NVGN)
finance.yahoo.com - November 23 at 7:38 PM
finance.yahoo.com logoNovogen Patent Covering Cantrixil and Trilexium Accepted in Australia (NASDAQ:NVGN)
finance.yahoo.com - November 11 at 7:04 PM
finance.yahoo.com logoPreclinical Studies Justify Mode of Delivery and Dosing Regimen for Anisina (NASDAQ:NVGN)
finance.yahoo.com - November 10 at 5:34 PM

Social

Novogen (NASDAQ:NVGN) Chart for Friday, September, 30, 2016


Last Updated on 9/30/2016 by MarketBeat.com Staff